Prochlorperazine (PCZ) was first approved by the FDA back in 1956 to treat psychosis, and, even though it’s been overtaken by newer antipsychotics, it’s still prescribed today to relieve nausea and vomiting. Now, Australian researchers are suggesting a new use for the drug: to improve the effectiveness of checkpoint inhibitors and other antibodies in cancer.

Bristol Myers Squibb has begun work with the Paris-based digital therapeutics developer Voluntis to create and test companion smartphone programs for cancer patients on its therapies, similar to a project previously dropped by Roche’s French pharma division.

In a high-stakes game for both companies, Shionogi is doubling down on its Tetra Therapeutics R&D deal with a buyout option wedded to key data coming out this month.

Cellectis has revised its deal with Servier, granting its partner worldwide rights to all its CD19 CAR-T therapies in return for €25 million ($27.6 million) and the control of candidates against five additional targets.

Novo Nordisk’s obesity drug Saxenda, which shares the ingredient liraglutide with the company’s diabetes treatment Victoza, has been shown to reduce appetite. The drug is an analog of naturally occurring GLP-1, a hormone that’s released after food intake to create the sensation of fullness. But the exact neuronal sites the drug affects remain largely unknown.

The active ingredient in Allergan’s eyelash-growing solution Latisse has found a new form with the FDA’s approval of the glaucoma drug bimatoprost developed as a long-term, biodegradable eye implant.

After analyzing all cell types in the human ovary, the researchers at Karolinska Institutet in Sweden have shed new insights into developmental biology. According to their new findings, egg stem cells do not exist. Nature Communications published the results, which could help improve the methods for treating involuntary childlessness.

First Extraterrestrial Protein Discovered

Breakthrough Bioscience Technologies In 2020 By MIT Technology Review

Boston-based hearing loss gene therapy biotech Akouos has grabbed a $105 million series B funding round.